REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
04/10/2026
Back to search
Official data from USPTO
AMGEN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
AMGEN
ST13
US500000078736498Class
5, 10, 35, 36, 41, 42, 44
Filing
78736498
Registration
3226919
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
40
Latest update
04/11/2026
Classification
Registered
Trademark type
Word
Nice classes
5, 10, 35, 36, 41, 42, 44
Filing date
10/19/2005
Registration date
04/10/2007
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/28/2017
Last transaction
04/11/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
1984-04-00
First use in commerce
1984-04-00
Drawing code
4
Owner type
03
Owner location
Thousand Oaks, CA, US
Examiner
FAIRBANKS, RONALD L
Law office
M80
Current location
GENERIC WEB UPDATE
Holders and representatives
Holders
Amgen Inc.
Representatives
Elsa D. Lemoine Amgen Inc.
Technical classification
Nice Classes
Class 5Class 10Class 35Class 36Class 41Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
House mark for a full line of pharmaceuticals; and pharmaceuticalsincluding human recombinant erythropoietin and erythropoiesis stimulating protein; pharmaceuticals for use in stimulating production of red blood cellswhite blood cells or platelets; pharmaceuticals for modulating calciumphosphorusparathyroid hormone levels in the blood or for treatment of hyperparathyroidismhypercalcemia or bone metabolism related disorders and diseases; pharmaceuticals for treating human immune diseases and conditions; pharmaceuticals for the treatment of viral infectionsneoplasticmetabolicautoimmune or inflammatory disorders; pharmaceuticals for the treatment of injury to epithelial cells and tissues; pharmaceuticals for modulating weight lossregulating reproductive function and promoting wound healingfor use in the treatment of obesitydiabeteshypertensiondyslipidemia and cardiovascular diseases and infertility; and support kits for patients afflicted with autoimmune or inflammatory disorderscomprised primarily of materials for wound dressing and sterilization and a device for delivery of a drug; one or more of the aforementioned pharmaceutical preparations sold in prefilled syringes
Class 10
a reusable device which assists in removing needle guards and adds stability to delivery of drugs by syringe and a reusable spring-loaded medical syringe holder for facilitating delivery of drugs by syringe
Class 35
billing services and referral services in the field of treatment for cancerchemotherapy and pharmaceutical products
Class 36
administration of patient reimbursement programs
Class 41
educational servicesnamely development and dissemination of educational materials of others in the fields of pharmaceutical products and treatment of medical disorders; conducting seminars regarding the use of prescription pharmaceutical products for medical disorders; providing a motivational and educational speaker featuring information regarding medical disorders
Class 42
medical research namelyclinical trial services
Class 44
patient support services relating to the treatment of medical disordersproviding online information regarding pharmaceutical preparations for treatment of various diseases; providing health and medical information about medical disorders; information servicesproviding medical information to cancer patients; information services relating to medical services via a global computer networkproviding medical consultancy and advisory services via a global computer network
Publications
History of USPTO decisions and trademark events.
40 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/25/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/25/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/25/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
02/25/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
02/25/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/29/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/29/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/29/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/29/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/29/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
04/29/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/07/2019
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/07/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
08/02/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
08/02/2018
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
03/28/2017
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
03/28/2017
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
03/28/2017
E89R
TEAS SECTION 8 & 9 RECEIVED
03/27/2017
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
04/10/2016
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
04/05/2013
C15P
REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/05/2013
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/05/2013
815F
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
03/25/2013
E815
TEAS SECTION 8 & 15 RECEIVED
03/25/2013
R.PR
REGISTERED-PRINCIPAL REGISTER
04/10/2007
PUBO
PUBLISHED FOR OPPOSITION
01/23/2007
NPUB
NOTICE OF PUBLICATION
01/03/2007
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
12/05/2006
ALIE
ASSIGNED TO LIE
12/05/2006
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/16/2006
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/01/2006
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/31/2006
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/31/2006
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
09/26/2006
GNRT
NON-FINAL ACTION E-MAILED
05/01/2006
CNRT
NON-FINAL ACTION WRITTEN
05/01/2006
DOCK
ASSIGNED TO EXAMINER
04/23/2006
NWAP
NEW APPLICATION ENTERED
10/25/2005
Continuous trademark protection
Get notified about every new filing that threatens AMGEN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.